# Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

> **NCT07662928** · PHASE2 · NOT_YET_RECRUITING · sponsor: **AIDS Malignancy Consortium** · enrollment: 43 (estimated)

## Conditions studied

- Adult Burkitt Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **PROCEDURE:** Echocardiography Test
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Etoposide
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT07662928
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2031-05-30
- **Final completion:** 2033-04-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662928, "Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*